|
PMS2CL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.5840999945691E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.01569999999551E-06 |
| Normal-vs-Stage2 |
8.994200E-04 |
| Normal-vs-Stage3 |
1.44140000046811E-07 |
| Normal-vs-Stage4 |
2.96940000366064E-08 |
| Stage1-vs-Stage2 |
8.504600E-01 |
| Stage1-vs-Stage3 |
2.848800E-01 |
| Stage1-vs-Stage4 |
3.533500E-02 |
| Stage2-vs-Stage3 |
3.744000E-01 |
| Stage2-vs-Stage4 |
1.267440E-01 |
| Stage3-vs-Stage4 |
3.573800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.81570000040909E-08 |
| Normal-vs-AfricanAmerican |
3.293600E-01 |
| Normal-vs-Asian |
5.58800000000081E-05 |
| Caucasian-vs-AfricanAmerican |
1.432030E-01 |
| Caucasian-vs-Asian |
8.766600E-01 |
| AfricanAmerican-vs-Asian |
1.860780E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.36649999996175E-06 |
| Normal-vs-Female |
5.69939999639502E-08 |
| Male-vs-Female |
4.646800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.39909999996579E-06 |
| Normal-vs-Age(41-60Yrs) |
1.54620000025751E-07 |
| Normal-vs-Age(61-80Yrs) |
4.33890000000048E-05 |
| Normal-vs-Age(81-100Yrs) |
6.821600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.168600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.919000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.558800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.089800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.469600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.079800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.560260E-03 |
| Classical-VS-Follicular |
5.308400E-01 |
| Classical-VS-Other |
2.050200E-01 |
| Classical-VS-Normal |
1.70359999995817E-06 |
| Tall-VS-Follicular |
3.433900E-02 |
| Tall-VS-Other |
9.669800E-01 |
| Tall-VS-Normal |
1.11810000147372E-08 |
| Follicular-VS-Other |
3.649000E-01 |
| Follicular-VS-Normal |
7.72970000000317E-05 |
| Other-VS-Normal |
3.379400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.38119999998554E-07 |
| Normal-vs-N1 |
7.86780000000542E-05 |
| N0-vs-N1 |
6.449000E-01 |
|
|
